Intervención fisioterapéutica en paciente neonatal

In earlier work, the research group successfully used artificial neural networks (ANNs) to estimate ventilation duration for adult intensive care unit (ICU) patients. The ANNs performed well in terms of correct classification rate (CCR) and average squared error (ASE) classifying the outcome into two classes: whether patients were ventilated for less than/equal to or for more than 8 h (< or >). The objective of new work was to apply this adult model to the estimation of ventilation with neonatal ICU (NICU) patient records. The performance obtained with the neonatal patients was comparable to that previously found with the adult database, again as measured in terms of a maximum CCR and a minimum ASE. The effectiveness of using the weight-elimination technique in controlling overfitting was again validated for the neonatal patients as it had been for our adult patients. It was concluded that the approach developed for ICU adult patients was also successfully applied to a different medical environment: neonatal ICU patients.

Objetivo: O objetivo geral do presente estudo consiste em analisar a produção científica sobre as complicações e riscos associados à nutrição parenteral prolongada em pacientes pediátricos e neonatais em unidades de terapia intensiva (UTI), visando garantir um maior conhecimento sobre essa prática terapêutica e suas implicações clínicas. Metodologia: As buscas foram realizadas por meio de pesquisas nas bases de dados PubMed Central (PMC). Foram utilizados três descritores em combinação com o termo booleano “AND”: Parenteral Nutrition, Neonatal Intensive Care Unit e Risk Factors. Foram encontrados 101 artigos, que foram posteriormente submetidos aos critérios de seleção. Após a aplicação dos critérios de inclusão e exclusão, 20 estudos foram selecionados, dos quais 10 artigos foram utilizados para análise detalhada. Resultados: A nutrição parenteral (NP) é essencial no cuidado de recém-nascidos prematuros e pacientes pediátricos gravemente doentes. No entanto, está associada a várias complicações potenciais, incluindo problemas hepatobiliares, infecciosos, mecânicos e metabólicos como hiperglicemia e hipertrigliceridemia. A administração de NP requer um planejamento cuidadoso e políticas de segurança rigorosas para minimizar riscos e maximizar benefícios clínicos. A NP prolongada pode levar a sérias complicações, como infecções da corrente sanguínea associadas a cateter, colestase e disfunção hepática. Conclusão: A NP prolongada em pacientes pediátricos e neonatais em UTIs está associada a riscos significativos que requerem vigilância rigorosa e intervenções preventivas. É crucial um monitoramento contínuo dos níveis de glicose, triglicerídeos e função hepática, além de práticas rigorosas de controle de infecção para garantir a segurança e eficácia da NP. Mais estudos são necessários para identificar estratégias de manejo que possam reduzir essas complicações e melhorar os resultados clínicos.

Candidemia is a major infectious complication in neonatal patients. The isolation of yeasts from blood is still the “gold standard” for its diagnosis, but other laboratory markers (i.e., circulating antigens) have been studied with varying specificities and sensitivities. The aim of this study was to evaluate the role of procalcitonin for the diagnosis of candidemia in neonatal patients at high risk. To verify if the use of different commercial methods can highlight dissimilar results of sensitivity and/or specificity, the determination of procalcitonin serum levels was estimated by two systems. Overall, 90 patients from a Neonatal Intensive Care Units were enrolled, of whom six developed Candida bloodstream infection. Four of six infants with candidemia had slight increase of procalcitonin values (0.5–1 ng/mL). Only one baby showed very high levels but he had fungal and bacterial sepsis at the same time, while no elevation was observed in the sixth patient. No statistically significant difference was observed between two different methods at the time of monitoring (p > 0.643). Both methods showed a sensitivity of 83.3 % at diagnosis, while the specificity was 73.8 and 63.1 % by methods A and B, respectively. In the light of the low sensibility and specificity of this assay, we can assume that the determination of procalcitonin would not seem to play a significant role in the diagnosis of fungal infection in neonatal patients.

No simple method exists for repeatedly measuring cardiac output in intensive care pediatric and neonatal patients. The purpose of this study is to present the theory and examine the in vitro accuracy of a new ultrasound dilution cardiac output measurement technology in which an extracorporeal arteriovenous tubing loop is inserted between existing arterial and venous catheters. Laboratory experiments. Research laboratory. None. None. In vitro validations of cardiac output, central blood volume, total end-diastolic volume, and active circulation volume were performed in a model mimicking pediatric (children 2-10 kg) and neonatal (0.5-3 kg) flows and volumes against flows and volumes measured volumetrically. Reusable sensors were clamped onto the arterial and venous limbs of the arteriovenous loop. A peristaltic pump was used to circulate liquid at 6-12 mL/min from the artery to the vein through the arteriovenous loop. Body temperature injections of isotonic saline (0.3-10 mL) were performed. In the pediatric setting, the absolute difference between cardiac output measured by dilution and cardiac output measured volumetrically was 3.97% +/- 2.97% (range 212-1200 mL/min); for central blood volume the difference was 4.59% +/- 3.14% (range 59-315 mL); for total end-diastolic volume the difference was 4.10% +/- 3.08% (range 24-211 mL); and for active circulation volume the difference was 3.30% +/- 3.07% (range 247-645 mL). In the neonatal setting the difference for cardiac output was 4.40% +/- 4.09% (range 106-370 mL/min); for central blood volume the difference was 4.90% +/- 3.69% (range 50-62 mL); and for active circulation volume the difference was 5.39% +/- 4.42% (range 104-247 mL). In vitro validation confirmed the ability of the ultrasound dilution technology to accurately measure small flows and volumes required for hemodynamic assessments in small pediatric and neonatal patients. Clinical studies are in progress to assess the reliability of this technology under different clinical situations.

ObjectivesDelivering aerosolized medication to patients during mechanical ventilation is a common practice in respiratory therapy for adult, pediatric, and neonatal populations. However, aerosol delivery in pediatric populations is inconsistent and challenging, impacting how the drug is delivered. Some factors that influence drug delivery efficiency are directly under the purview of the clinician or therapist administering the drugs. However, excessive variability exists amongst clinicians and therapists working at the same site and between different sites. This review aims to systematically summarize the literature to identify current practice variations, identify common practices, and provide suggestions to guide future research in this area. In addition, this scoping review aims to identify the available evidence and knowledge gaps in the literature regarding the delivery of aerosolized medication to pediatric populations during mechanical ventilation. More specifically, the question that guided our research was: What are the best strategies for optimizing aerosol delivery of medication to pediatric patients, including neonates, while on mechanical ventilation?MethodsA scoping review, using the Joanna Briggs Institute methodology, was conducted until September 2022 in the CINAHL, EMBASE (Ovid), and Medline (Ovid) databases. Our initial search yielded 248 articles. After screening the titles, abstracts, and full text of the articles according to inclusion and exclusion criteria, five articles were analyzed.ResultsWe identified three main topics for discussion: the type of device used for administering aerosolized medication, appropriate mechanical ventilation settings, and optimal placement of the nebulizer delivery system.ConclusionOf the three topics we intended to discuss, we only found enough evidence to suggest using mesh nebulizers to increase aerosol deposition. We found conflicting or outdated results for the other two topics. This demonstrates a significant gap in the literature since aerosol medications are routinely administered to mechanically ventilated neonatal and other pediatric patients.

Background Pharmacokinetics of beta-lactams vary widely in neonatal and pediatric patients due to developmental biology and critical illness. Cefepime (FEP), meropenem (MEM), and piperacillin/tazobactam (TZP) are highly susceptible to pharmacokinetic changes as hydrophilic, small molecules with renal clearance. Subtherapeutic levels are associated with clinical and microbiologic failure, and supratherapeutic levels associated with toxicity. Beta-lactam therapeutic drug monitoring (TDM) may optimize the effectiveness and safety of these agents. The purpose of this investigation is to describe the % of pediatric and neonatal patients with beta-lactam serum levels within target range. Methods In August 2023, TDM launched at the Mayo Clinic Children’s Center for select patients treated with FEP, MEM, or TZP with expected durations ≥ 48 hours, or who were on kidney replacement therapy (KRT), extracorporeal membrane oxygenation (ECMO), weighed &amp;gt; 120 kg, had a BMI &amp;gt; 95th percentile, or at the discretion of pediatric ID team. Validated drug assays were performed daily, Monday through Friday. A two-level sampling strategy was preferred with a peak 1 hour after the end of the infusion and a trough 30 minutes before the next dose. Empiric trough target ranges were set at FEP 8-50 mg/L, MEM 2-30 mg/L, and piperacillin 16-150 mg/L. These target ranges were adjusted with confirmed microbiology to a time above the minimum inhibitory concentration of the organism for 100% of the dosing interval (100%T &amp;gt; MIC). Results From August 2023 to April 2024, 74 episodes of TDM were performed on 45 patients. Thirty-seven (82%) patients were in an intensive care unit (ICU) at the time of TDM, 8/45 (22%) of whom were in the neonatal ICU. Target range was achieved in 67% of patients on FEP, 50% on MEM, and 52% on TZP. Median (IQR) trough values were 22.1 (8.6, 44.2) mg/L for FEP, 0.6 (0, 4.1) mg/L for MEM, and 15.5 (3.8, 27.1) mg/L for TZP. Seven levels were above target for FEP and 0 for MEM and TZP. Seven levels were below target for FEP, 4 for MEM, and 11 for TZP. Conclusion Implementation of a TDM program for FEP, MEM and TZP in pediatric and neonatal patients revealed drug levels frequently outside target range. TDM may facilitate dose individualization to optimize medication efficacy and minimize toxicity. Disclosures Raymond Stetson, MD, MS, Moderna: Grant/Research Support Christina G. Rivera (O'Connor), Pharm.D, Gilead Sciences: Board Member Erin F. Barreto, PharmD, MSc, Baxter Health: Advisor/Consultant|Wolters Kluwer: Advisor/Consultant

Reliable vascular access is one of the most essential features of modern medical care. Unfortunately, the intravascular devices (IVDs) needed to establish reliable access are associated with significant potential for producing bloodstream infection (BSI). More than 250 000 IVD-related BSIs occur in the United States each year, each associated with prolongation of hospital stay, a 12% to 25% attributable mortality, and an added cost to health care of $35 000.1 A recent meta-analysis has shown that rates of IVD-related BSI in children and in neonates with different types of IVDs are similar to those encountered in adults.2 Detailed evidence-based recommendations for prevention of IVD-related BSI were first published in 1973,3 then, for the first time by an expert panel convened by the Centers for Disease Control and Prevention’s (CDC’s) Hospital Infection Control Practices Advisory Committee (HICPAC) in 1981,4 and updated in 1996.5 With wide acceptance and consistent implementation of these guidelines, the incidence of central venous catheter (CVC)-associated BSI in US intensive care units (ICUs) has decreased 40% over the past decade.6 HICPAC aided by a panel of authorities has again updated the IVD Guideline,7 with specific recommendations—scored by the quality of the underlying scientific evidence, ranging from consensus theoretical rationale to well-designed, prospective, randomized clinical trials—that cover all aspects of IVD care in both adult and pediatric patients (Table 1). View this table: TABLE 1. Summary of CDC HICPAC Guideline for Prevention of IVD-Related BSIs There are 2 important changes in the new Guideline that apply both to pediatric and adult patients. First, given the evidence for the importance of skin microorganisms in the pathogenesis of IVD-related infection,1 measures to reduce cutaneous colonization of the insertion site would seem of highest priority, particularly the antiseptic used for disinfection of the site before insertion and in … Reprint requests to (J.S.G.) St Joseph Regional Medical Center, 5000 West Chambers St, Milwaukee, WI 53210. E-mail: jsgarland{at}hotmail.com

Guidelines on transfusion for fetuses, neonates and older children.

Neonatal multicystic dysplastic kidney with mass effect: A systematic review

PP04.15 – 2395: Cortical laminar necrosis after neonatal and childhood arterial ischemic stroke. A relevant finding?

Although the use of extracorporeal membrane oxygenation (ECMO) significantly improves survival in patients with persistent respiratory or cardiovascular failure, it also induces physiologic stress and disrupts homeostatic mechanisms. Patients undergoing ECMO support at our institution have required widely variable quantities of calcium supplementation for maintenance of normal calcium levels. Our primary objective was to assess the frequency of calcium abnormalities in pediatric and neonatal ECMO patients. Secondary objectives included quantifying electrolyte supplementation provided during ECMO and determining the relationships between calcium abnormalities and ECMO duration, mortality, and intensive care and hospital length of stay. We performed a single-center retrospective chart review of all patients less than 18 years of age who received ECMO support between July 1, 2013, and May 31, 2016. Clinical and laboratory data were reviewed for each patient for the duration of ECMO support, and the incidence of ionized calcium outside the reference range of 1.1 to 1.4 mmol/L beyond the first 24 hours of ECMO was recorded. Seventy-eight patients were included in the study: 51 patients (65%) experienced at least one reading outside the normal ionized calcium range, while 27 patients (35%) were normocalcemic during their ECMO course. There were no differences between groups in the quantities of calcium, phosphate, or vitamin D administered during ECMO. Abnormal calcium levels were associated with a longer duration of ECMO (median 9 days vs 6 days, p = 0.0054), prolonged ICU length of stay (median 33 vs 18 days, p = 0.0055), and prolonged hospital length of stay (median 52 vs 40 days, p = 0.0239). No significant differences were found in survival to decannulation or survival to hospital discharge. Calcium abnormalities occur frequently in pediatric and neonatal patients during ECMO and are associated with worse patient outcomes. The underlying physiology of these changes is thought to be related to ECMO-induced disruption of normal calcium homeostasis.

Risk factors for ventilator-associated pneumonia in neonatal intensive care unit patients

Infants admitted to neonate intensive care units (NICUs) are placed in incubators to maintain body temperature and condition, which undergo normal radiographs and are exposed to radiation. Furthermore, different incubator structures in different hospitals exhibit varying object to image receptor distance (OID), source to image receptor distance (SID), presence of canopy, which results in variations in X-ray radiation conditions and doses absorbed by the neonatal patients. To measure organ dose exposed to neonatal patient in different incubator settings. A portable X-ray was performed on a neonatal patient placed in an incubator to identify disease progress, the injection path of the drug, and various factors. To minimize direct contact between neonatal patients and image receptor, radiologic technologists place the image receptor on a tray underneath the incubator and place the portable X-ray tube on top of the acrylic canopy of the incubators. SID and OID settings and value of organ dose exposed to the patient varied based on the incubator structure, and the organ absorbed dose was determined using Monte Carlo N-Particle (MCNP) simulation, PC-based Monte Carlo program (PCXMC) 2.0 simulation, and neonate phantoms. Evaluations of organ dose of neonatal patients in three hospitals with different incubator settings reveal that the average organ dose differs by 36% depending on change in OID and SID settings and reduces by 10% with an acrylic canopy. Therefore, owing to the presence of an acrylic canopy on the top of the incubator and the longer SID with the corresponding shorter OID, a lower dose was absorbed by organs of neonatal patient. Our results provide proof that proper incubator standard decreases organ dose to neonatal patient during continuously diagnostic X-ray procedure.

Establishment of evidence-based best practices for preventing surgical site infection (SSI) in neonates is needed. SSI in neonates, especially those with a low birth weight, is potentially life-threatening. We aimed to identify risk factors associated with SSI in neonates. A retrospective review was performed using 2007-2016 admission data from our institution. Neonatal patients who were admitted to the neonatal intensive care unit and underwent surgery were evaluated for a relationship between development of SSI and perinatal or perioperative factors and methicillin-resistant Staphylococcus aureus (MRSA) colonization during hospitalization. One hundred and eighty-one patients were enrolled in this study. Overall SSI incidence was 8.8%. Univariate analysis showed that SSI was significantly more frequent in both patients with contaminated or dirty wound operations and patients with MRSA colonization during hospitalization. Both of these factors were identified as independent risk factors for SSI by multivariate analysis [hazard ratio (HR): 6.1, 95% confidence interval (CI) 2.0-19.9; HR: 3.3, 95% CI 1.1-10.4, respectively]. This study identified contaminated or dirty wound operations and MRSA colonization during hospitalization as risk factors for SSI in neonates. MRSA colonization may be a preventable factor, unlike previously reported risk factors.

An algorithm for QT interval monitoring in neonatal intensive care units